Novartis won’t increase its U.S. drug prices for the rest of 2018, the Switzerland-based drugmaker said, days after Pfizer took a similar step in the face of criticism from President Donald Trump.
from WSJ.com: US Business https://ift.tt/2mrUS9J
via IFTTT
No comments:
Post a Comment